Timing of Necrosectomy After Endoscopic Drainage of Walled-off Pancreatic Necrosis (WON)
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 14, 2022
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods for treating a serious condition called walled-off pancreatic necrosis (WON), which can happen after pancreatitis and may cause severe illness. The trial compares a standard approach, where doctors first drain the area and then perform surgery if needed, to a newer method where doctors do surgery right away while placing a drain. The goal is to see which method helps patients recover faster and requires fewer surgeries.
To participate in this trial, you need to be an adult over 18 years old with a confirmed diagnosis of WON, typically seen on imaging tests. You should also have symptoms like ongoing pain, nausea, or weight loss due to this condition. However, there are some reasons you might not be eligible, such as having had previous surgeries for similar issues or being pregnant. If you join the study, you can expect close monitoring and care from the medical team as they gather information on your recovery with either treatment method.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult (≥18 years of age) patients
- • 2. Diagnosis of walled-off pancreatic necrosis (WON) based on imaging criteria based on the revised Atlanta classification5
- • 3. Documented history of acute pancreatitis
- • 4. Suspected or confirmed infected WON and/or symptomatic WON causing (i) persistent pancreatic-type pain, and/or ii) gastric outlet or biliary obstruction, and/or (iii) ongoing systemic illness, anorexia, and weight loss, and/or (iv) rapidly enlarging WONs, and/or (v) infected WON\*
- • 5. WON identified at contrast-enhanced computed tomography (CECT) and deemed amenable for EUS-guided drainage
- • 6. WON with a solid component \>30% and/ or percentage of necrosis \>= 30%
- Exclusion Criteria:
- • 1. Previous invasive interventions for necrotising pancreatitis
- • 2. An acute flare up of chronic pancreatitis
- • 3. Recurrent acute pancreatitis
- • 4. Indicated for emergency laparotomy (i.e. abdominal compartment syndrome, perforation of a visceral organ, bleeding and bowel ischaemia)
- • 5. Contraindications to endoscopic drainage: previous total gastrectomy, gastric bypass surgery, prior surgery for pancreas-related diseases
- • 6. WON not adherent to the GI wall or not accessible for endoscopic drainage
- • 7. Coagulopathy (INR \>1.5), and/or thrombocytopenia (platelets \<50,000/mm3)
- • 8. Pregnancy
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, Australia
Bangkok, Thailand
Bangkok, Thailand
Pune, India
Hyderabad, Andhra Pradesh, India
Valladolid, Spain
Hong Kong, Hong Kong
Haryana, India
Asan, Korea, Republic Of
Asan, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials